Skip to Content

PolyNovo (PNV)

PNV $0.87

20 minute delayed

Today ▼ -1.69%
1 year return ▼ -25.32%
Volume 366,138
Div yield —
PE ratio 82.86
52 week range
0.81 1.30

14 days free access

Join Market Matters and get full access to all our Opinion + Action

Learn more

Performance

Advanced charting functionality with the ability to amend timeframes, chart type & indicator selection, powered by TradingView.

Share price activity

Displays share price activity. Volume = number of shares traded, Turnover = value of shares traded, VWAP = volume-weighted average price for the day, sourced from Morningstar.
Last (Price)
0.87
Change
▼ -0.02 (-1.69)
Bid / Ask
0.87 - 0.88
Volume
366,138
Turnover
319,697
Open
0.89
Day Range
0.87 - 0.89
VWAP
0.87
Prev Close
0.89
Last Trade
17/11 4:10pm
Displays useful ratios for the security, NB the pricing date used, sourced from Morningstar.
Ratios
Currency (Price/reporting): AUD/AUD
Exchange Rate: 1.0000
Price, volume and trading statistics for the security, sourced from Morningstar.
Price - closing or last bid 0.89
Price - 12 month high 1.30
Price - 12 month low 0.81
Pricing date 12 NOV 2026
Volume - avg. trading volume for the last ten days 1.06
Market capitalization 611.40
12 Month High price date 24 DEC 2025
12 Month Low price date 28 JUL 2026
Volume - avg. trading volume for the last 3 months 1.57
Price - 1 Day % Change -1.12%
Price - 13 week price percent change -6.35%
Price - 26 week price percent change -6.35%
Price - 5 Day % Change -2.21%
Price - 52 week price percent change -28.63%
Price - YTD price percent change -28.05%
Price % Change Month To Date -6.84%
Earnings, dividends, cash flow and book value per share, sourced from Morningstar.
EPS excluding extraordinary items - most recent fiscal year 0.011
EPS excluding extraordinary items - trailing 12 month 0.011
EPS Normalized - most recent fiscal year 0.010
Revenue/share - most recent fiscal year 0.206
Revenue/share - trailing 12 month 0.206
Book value per share - most recent fiscal year 0.131
Book value per share - most recent half-year 0.131
Book value (tangible) per share - most recent fiscal year 0.131
Book value (tangible) per share - most recent half-year 0.131
Cash per share - most recent fiscal year 0.051
Cash per share - most recent half-year 0.051
Cash Flow per share - most recent fiscal year 0.033
Cash Flow per share - trailing 12 month 0.033
Dividend per share - most recent fiscal year —
Dividends per share - trailing 12 month 0.000
EBITD per share - trailing 12 month 0.016
EPS Basic excluding extraordinary items - most recent fiscal year 0.011
EPS Basic excluding extraordinary items - trailing 12 month 0.011
EPS including extraordinary items - most recent fiscal year 0.011
EPS including extraordinary items - trailing 12 month 0.011
Free Cash Flow per share - trailing 12 month 0.013
Valuation multiples such as P/E, price to sales, price to book and enterprise value ratios, sourced from Morningstar.
P/E excluding extraordinary items, most recent fiscal year 84.29
P/E Normalized, most recent fiscal year 89.53
Price to sales - most recent fiscal year 4.31
Price to Tangible Book - most fiscal year 6.77
Price to Free Cash Flow per Share - most recent fiscal year 66.45
Price to Cash Flow per share - trailing 12 month 26.78
Price to Book - most recent fiscal year 6.74
P/E excluding extraordinary items high, trailing 12 months 100.48
P/E excluding extraordinary items low, trailing 12 months 48.41
Net Debt, LFI -11.07
Net Debt, LFY -17.86
Dividend Yield - 5 Year Average —
Dividend Yield - indicated annual dividend divided by closing price —
Current Dividend Yield - Common Stock Primary Issue, LTM 0.00%
Cash flow, liquidity and leverage measures, sourced from Morningstar.
Free Cash Flow - most recent fiscal year 9.31
LT debt/equity - most recent fiscal year 16.01%
Payout ratio - most recent fiscal year —
Total debt/total equity - most recent fiscal year 19.42%
LT debt/equity - most recent half-year 18.51%
Total debt/total equity - most recent half-year 21.88%
Free Cash Flow - trailing 12 month 9.31
Payout ratio - trailing 12 month —
Key income statement lines for the most recent fiscal year, in millions, sourced from Morningstar.
Revenue - most recent fiscal year 143.71
Revenue - trailing 12 month 143.71
EBITD - most recent fiscal year 11.29
EBITD - trailing 12 month 11.29
Earnings before taxes - most recent fiscal year 7.82
Earnings before taxes - trailing 12 month 7.82
Net Income available to common - most recent fiscal year 7.34
Net Income available to common - trailing 12 months 7.34
Earnings before taxes Normalized - most recent fiscal year 7.36
Net Income Available to Common, Normalized - most recent fiscal year —
Earnings per Share, Normalized, Excluding Extraordinary Items, Avg. Diluted Shares Outstanding, TTM 0.01
Profitability margins for the most recent fiscal year, sourced from Morningstar.
Net Profit Margin % - 1st historical fiscal year 5.11%
Net Profit Margin % - trailing 12 month 5.11%
Operating margin - 1st historical fiscal year 7.28%
Operating margin - trailing 12 month 7.28%
Pretax margin - trailing 12 month 5.44%
Pretax margin - 1st historical fiscal year 5.44%
Operating Margin - 5 year average 0.37%
Pretax Margin - 5 year average 0.53%
Free Operating Cash Flow/Revenue, 5 Year Average -5.12%
Free Operating Cash Flow/Revenue, TTM 6.48%
Net Profit Margin - 5 year average 2.03%
Returns on average assets and equity for the fiscal year, the trailing 12 months and as 5 year averages, and net income and revenue per employee in whole currency, sourced from Morningstar.
Return on average assets - most recent fiscal year 5.75%
Return on average assets - trailing 12 month 5.75%
Return on average equity - most recent fiscal year 8.57%
Return on average equity - trailing 12 month 8.57%
Return on average assets - 5 year average 1.69%
Return on average equity - 5 year average 2.30%
Net Income/employee - most recent fiscal year —
Revenue/employee - most recent fiscal year —
Growth in revenue, earnings, dividends and book value over recent periods, sourced from Morningstar.
Revenue growth rate, 5 year 37.58%
EPS growth rate, 5 year —
Growth rate% - dividend, 3 year —
Revenue/share (5 yr growth) 36.05%
Growth rate% - Revenue, 3 year 30.11%
Growth rate% - EPS, 3 year —
Book value per share growth rate, 5 year 31.18%
Capital Spending growth rate, 5 year 31.06%
Earnings Before Interest, Taxes, Depreciation & Amortization, 5 Year CAGR —
Displays analyst’s forecasts for key measures. The estimates can be expanded to see the spread of the calls. Full lines = reported, and dotted lines are forward estimates. Click a measure to add or remove it from the chart, sourced from Morningstar.

Financial forecast (AUD, millions except per share)

Actuals Estimates
2026 202720282029
Financial metrics can be plotted on the graph to see trends. Multiple metrics from multiple statements can be plotted against each other, sourced from Morningstar.

Financials (AUD, millions)

Period end: JUN 22JUN 23JUN 24JUN 25JUN 26
Fiscal year: 20222023202420252026
Period length: 12 months12 months12 months12 months12 months
Displays all company announcements released by the company to the exchange, sourced from Morningstar.

Announcements

DATE TIME HEADING PAGES

Opinion

Action

Business Summary

Polynovo earns majority of its revenue from U.S sales of its NovoSorb Biodegradable Temporizing Matrix, or NovoSorb BTM. The product is a patented biodegradable synthetic scaffold to support the regeneration of the dermis when lost throughsurgery, trauma, burns or other causes of tissue loss. Once the product is applied to a wound, it takes a few weeks for the dermal layer to fully integrate within the polymer scaffold before a clinician can delaminate the outer layer. A small wound would then close either naturally or with a dressing, while a larger wound would close through a split-skin graft or alternative product such as Avita's RECELL. NovoSorb BTM then slowly degrades to harmless byproducts which are fully absorbed in roughly 18 months.

Back to top